CSF1R

Macrophage colony-stimulating factor 1 receptor

244,583 patent compounds predicted against CSF1R, 165,735 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Linifanib (SCHEMBL93804)	1.00	10/20
SCHEMBL60289	0.48	7/20
SCHEMBL58735	0.47	7/20
SCHEMBL58313	0.59	6/20
SCHEMBL58543	0.57	6/20
SCHEMBL60464	0.57	6/20
SCHEMBL59547	0.49	6/20
SCHEMBL90887	0.49	6/20
SCHEMBL90935	0.49	6/20
SCHEMBL66159	0.49	6/20
SCHEMBL60366	0.47	6/20
SCHEMBL58496	0.44	6/20
SCHEMBL60035	0.43	6/20
SCHEMBL58550	0.55	5/20
SCHEMBL57890	0.53	5/20
SCHEMBL58732	0.51	5/20
SCHEMBL58416	0.50	5/20
SCHEMBL56997	0.49	5/20
SCHEMBL59957	0.49	5/20
SCHEMBL65684	0.48	5/20

Germline variants in CSF1R on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CSF1R gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CSF1R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of Vimseltinib for Tenosynovial Giant Cell Tumor	PHASE3	ACTIVE_NOT_RECRUITING
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)	PHASE3	ACTIVE_NOT_RECRUITING
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.	PHASE3	ACTIVE_NOT_RECRUITING
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	PHASE1/PHASE2	RECRUITING
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib	PHASE1/PHASE2	COMPLETED
Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS	PHASE1/PHASE2	NOT_YET_RECRUITING
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	PHASE1/PHASE2	RECRUITING
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor	PHASE1/PHASE2	COMPLETED
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma	PHASE2	COMPLETED
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma	PHASE1/PHASE2	COMPLETED
The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy	PHASE2	COMPLETED
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis	PHASE2	COMPLETED
Safety and Efficacy of PMT Therapy of hPAP	PHASE1/PHASE2	RECRUITING
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer	PHASE2	RECRUITING
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome	PHASE1/PHASE2	COMPLETED
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia	PHASE1/PHASE2	COMPLETED
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma	PHASE2	COMPLETED
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment	PHASE2	COMPLETED
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma	PHASE1	WITHDRAWN
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Interleukin-34 Level in Periodontal Disease	nan	UNKNOWN
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET	nan	RECRUITING
IL-34 Levels in Various Types of Periodontitis	nan	COMPLETED
Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions	nan	RECRUITING
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML	nan	RECRUITING
Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF	nan	COMPLETED
Interleukin-34 in Stage I and II Periodontitis	nan	COMPLETED
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors	nan	RECRUITING
Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CSF1R binder may also engage these)

Protein	Name	Similarity
Q00495	—	1.000	Q00495 →
P13369	—	1.000	P13369 →
P09581	—	1.000	P09581 →
P00545	—	1.000	P00545 →
Q6QNF3	—	1.000	Q6QNF3 →
P35546	—	1.000	P35546 →
PDGFRB	Platelet-derived growth factor receptor beta	1.000	landscape →
Q8JFR5	—	1.000	Q8JFR5 →
Q91ZT1	—	0.999	Q91ZT1 →
Q8AXC7	—	0.998	Q8AXC7 →
Q9I8N6	—	0.997	Q9I8N6 →
P79750	—	0.997	P79750 →
P35917	—	0.997	P35917 →
P05622	—	0.997	P05622 →
Q28889	—	0.997	Q28889 →
Q8UVR8	—	0.996	Q8UVR8 →
Q8AXC6	—	0.996	Q8AXC6 →
B6ZK77	—	0.996	B6ZK77 →
Q05030	—	0.996	Q05030 →
P26619	—	0.995	P26619 →
P52583	—	0.995	P52583 →
Q92729	—	0.995	Q92729 →
P43481	—	0.995	P43481 →
Q2HWD6	—	0.995	Q2HWD6 →
Q8K1S3	—	0.995	Q8K1S3 →
Q62838	—	0.994	Q62838 →
JAK3	Tyrosine-protein kinase JAK3	0.994	landscape →
Q28317	—	0.994	Q28317 →
P79749	—	0.994	P79749 →
Q76II0	—	0.994	Q76II0 →